Federal health officials have moved to stop Medicaid and CHIP from covering hormone therapies and surgeries used to alter a child’s sex, citing safety gaps and long-term risks, while keeping mental health care in place and allowing a limited phase-out window for ongoing treatments.
The Centers for Medicare & Medicaid Services announced that taxpayer-funded coverage for cross-sex hormones, puberty blockers and related surgical procedures will end under Medicaid and the Children’s Health Insurance Program. This change is presented as a protection for minors and a return to evidence-based stewardship of federal health dollars.
Dr. Mehmet Oz described the rule as “consistent with [the Trump administration’s] commitment to protect children from experimental and life-altering sex-rejecting procedures that carry serious long-term health risks and lack sufficiently reliable evidence of clinical benefit.” That line of reasoning guided the new policy and fuels the argument that federal funds should not underwrite treatments with unresolved safety profiles.
The rule does not strip away mental health services for young people with gender dysphoria or other conditions, and officials emphasized that counseling and related behavioral care remain covered under Medicaid and CHIP. Supporters say this distinction preserves access to assessment and psychological support while halting medical interventions they view as premature.
Health officials and supporters pointed to documented potential harms from these procedures, including infertility, impaired sexual function, diminished bone density, and altered brain development. That list of possible outcomes was used to argue that irreversible or long-lasting physiological effects should not be paid for by taxpayers when high-quality evidence of benefit is lacking.
HHS under Secretary Robert F. Kennedy Jr. reviewed domestic and international studies before the reversal, with particular attention to external reviews that flagged evidence gaps. Secretary Kennedy said, “Today, we are ending federal taxpayer funding for sex-rejecting procedures on children,” and warned that “These interventions carry serious risks and can cause irreversible harm. The federal government will no longer use Medicaid and CHIP dollars to fund procedures that fail to meet the evidentiary standard our children deserve.”
Conservative leaders framed the move as a corrective after years of policies that, in their view, allowed federal money to bankroll life-altering interventions for minors. The argument is straightforward: taxpayers should not be forced to finance treatments that appear experimental and may leave lifelong consequences for children who cannot yet give informed consent.
HHS also cited international analysis as influential in the decision, including a high-profile review that found fast-developing medical practice outpacing the evidence base. Officials said the research “identified significant evidence gaps” and “documented serious safety concerns” that together undercut the case for federal coverage of these procedures.
HHS Press Secretary Emily Hilliard added a clear policy stance, saying, “The Trump Administration is drawing a clear line: America’s children will not be subjected to life-altering interventions on the taxpayer’s dime without reliable evidence of safety and clinical benefit.” She continued, “Under the leadership of Secretary Kennedy, federal health care dollars will support evidence-based care that protects children and puts their long-term health first,” and warned that “American taxpayers should never be forced to finance interventions when the evidence of benefit is insufficient and the potential consequences for children can be serious and irreversible.”
Officials also announced a transition period to avoid abrupt disruption for youths already receiving treatments, allowing Medicaid and CHIP funding for existing hormone regimens to continue for six months from the rule’s effective date. That tapering-off window was described as a practical measure to balance immediate protections with continuity of care for children already in treatment programs.
Graduate Student, wife, engaged political and legal writer.